Aging is driven by progressive cellular damage, dysfunction, and senescence, a therapeutically actionable contributor to chronic inflammation, tissue degeneration, and age-related disease. However, senolytic and senomorphic translation remains constrained by senescent-cell heterogeneity, narrow therapeutic windows, inconsistent exposure, limited tissue penetration, uncertain nanoparticle accumulation in poorly perfused aged organs, and the absence of definitive clinical efficacy. Nanomedicine should therefore be viewed not as generic drug packaging, but as a strategy to improve the senolytic index through controlled exposure, multi-step selectivity, intracellular delivery, and context-responsive release. This review critically evaluates lipid-based, polymeric, hybrid, and biomimetic nanoplatforms by asking whether they improve target engagement, functional recovery, and safety over free drugs, rather than merely increasing encapsulation efficiency or in vitro cytotoxicity. Emphasis is placed on assay-aware interpretation of quantitative claims, limitations of single-marker targeting, variability of EPR-like behavior in aging tissues, manufacturability, and regulatory readiness. Overall, nanomedicine-based senotherapy is highly promising but not yet clinically de-risked; meaningful progress will require disciplined biology-to-design integration, human-tissue validation, and rigorous benchmarking against clinically relevant outcomes.
Singh et al. (Tue,) studied this question.